Research map: Glypican-3-targeted therapy in hepatocellular carcinoma: biological insights and therapeutic strategies
Back to the article
Papers in this map
Understanding the tumor immune microenvironment (TIME) for effective therapy
· Mikhail Binnewies · 2018 · 6348 citations · Cited by this paper
Glypican-3-targeted bioconjugates for hepatocellular carcinoma: design, engineering, and translational applications
· Yi Liu · 2026 · Cites this paper
The role of STAT3 in regulating ferroptosis in cancer: molecular mechanisms and targeted therapeutic perspectives
· 2026 · Related
Strategies and challenges for the next generation of antibody–drug conjugates
· Alain Beck · 2017 · 2288 citations · Cited by this paper
b-AP15 enhances TRAIL-induced cell death in HNSCC via the induction of ROS/JNK/DR5 signalling
· 2026 · Related
Human chimeric antigen receptor macrophages for cancer immunotherapy
· Michael Klichinsky · 2020 · 1499 citations · Cited by this paper
COL3A1 promotes gastric cancer progression by activating PI3K/AKT signaling
· 2026 · Related
Bispecific antibodies: a mechanistic review of the pipeline
· Aran F. Labrijn · 2019 · 1332 citations · Cited by this paper
Inhibiting CXCL12/CXCR4 axis enhances T cell activity in gastric cancer
· 2026 · Related
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
· Mariana Capurro · 2003 · 923 citations · Cited by this paper
Memory programming and new manufacturing paradigms in CAR-T cell therapy
· 2026 · Related
Toxicity and management in CAR T-cell therapy
· Challice Lee Bonifant · 2016 · 908 citations · Cited by this paper
Dioscin suppresses tumorigenesis and overcomes radioresistance by promoting ubiquitination-mediated degradation of Mcl-1
· 2026 · Related
Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion
· Nicole E. Scharping · 2021 · 902 citations · Cited by this paper
SPARC family proteins: matricellular modulators of cancer progression and therapeutic resistance
· 2026 · Related
Natural killer cells in cancer biology and therapy
· Song‐Yang Wu · 2020 · 897 citations · Cited by this paper
HOXC11 promotes head and neck squamous cell carcinomas (HNSCC) progression by regulating SPHK1 through the Wnt signaling pathway
· 2026 · Related
Antibody–drug conjugates come of age in oncology
· Charles Dumontet · 2023 · 849 citations · Cited by this paper
The Tumor-suppressive role of CNTNAP2 in glioma: Dual regulation of the NDN-ERK axis and M2 macrophage polarization
· 2026 · Related
T cell receptor (TCR) signaling in health and disease
· Kinjal Shah · 2021 · 617 citations · Cited by this paper
A phase I study of multi-HLA-binding peptides derived from heat shock protein 70/glypican-3 and a novel combination adjuvant of hLAG-3Ig and Poly-ICLC for patients with metastatic gastrointestinal cancers: YNP01 trial
· 2020 · Related
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
· Gavin M. Bendle · 2010 · 450 citations · Cited by this paper
Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
· Fubo Zhou · 2017 · 407 citations · Cited by this paper
Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
· Noelle V. Frey · 2018 · 404 citations · Cited by this paper
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
· Donghua Shi · 2020 · 386 citations · Cited by this paper
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
· Huiping Gao · 2014 · 313 citations · Cited by this paper
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
· Yu Sawada · 2012 · 304 citations · Cited by this paper
Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix
· Wenlong Zhang · 2019 · 295 citations · Cited by this paper
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
· Paul W. Shafer · 2022 · 271 citations · Cited by this paper
Glypican-3–Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma
· Sai Arun Batra · 2020 · 265 citations · Cited by this paper
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
· David Steffin · 2024 · 256 citations · Cited by this paper
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
· Christopher Sloas · 2021 · 246 citations · Cited by this paper
CAR-macrophage: A new immunotherapy candidate against solid tumors
· Yizhao Chen · 2021 · 243 citations · Cited by this paper
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
· Beatriz Sánchez-Correa · 2019 · 218 citations · Cited by this paper
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
· Takahiro Ishiguro · 2017 · 213 citations · Cited by this paper
First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma
· Andrew Xiuxuan Zhu · 2013 · 197 citations · Cited by this paper
Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy
· Nader El-Sayes · 2021 · 197 citations · Cited by this paper
Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
· Amani Makkouk · 2021 · 197 citations · Cited by this paper
Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma
· Min Yu · 2017 · 189 citations · Cited by this paper
Source: OpenAlex (CC0)